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Background: Cadherin 12 (CDH12), which encodes a type II classical cadherin from the cadherin superfamily, may
mediate calcium-dependent cell adhesion. It has been demonstrated that CDH12 could play an important role in
the invasion and metastasis of salivary adenoid cystic carcinoma. We decided to investigate the relationship be-
tween CDH12 expression level and clinicopathologic variables in colorectal carcinoma (CRC) patients and to explore
the functions of CDH12 in tumorigenesis in CRC.
Methods: The expression levels of CDH12 in colorectal carcinoma tissues were detected by immunohistochemistry.
Real-time PCR and Western Blot were used to screen CDH12 high-expression cell lines. CCK-8 assay was used to
detect the proliferation ability of CRC cells being transfected by shRNAs against CDH12. The wound assay and trans-
well assay were performed to test migration and invasion ability. The importance of CDH12 in cell-cell junctions
was detected by cell adhesion assay and cell aggregation assay. Endothelial tube formation assay was used to test
the influence of CDH12 on angiogenesis.
Results: Statistical analysis of clinical cases revealed that the positive rate of CDH12 was higher in the CRC tumor
tissues compared with the adjacent non-tumor tissues. The expression levels of CDH12 in CRC patients are signifi-
cantly correlated with invasion depth. Consistently, the ability of proliferation, migration and invasion were sup-
pressed when CDH12 was decreased in CRC cells transfected with shRNAs. Cell adhesion assay and cell aggregation
assay presented that tumor cells tend to disperse with the lack of CDH12. Endothelial tube formation assay showed
that down-regulation of CDH12 could obviously inhibit the process of angiogenesis, implying that CDH12 may play
an important role in tumor metastasis.
Conclusion: Our results showed that CDH12 promotes proliferation, migration, invasion, adhesion and
angiogenesis, suggesting that CDH12 may be an oncogene in colorectal cancer. CDH12 is expected to become a
new diagnostic and prognostic marker and a novel target of the treatment of colorectal cancer.
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Cadherin adhesion molecule is one of the ubiquitous types
of cell-cell interactions required for the maintenance of
complex tissue morphology. Traditionally, cadherins are
membrane-spanning Ca2+-dependent homophilic adhesion
receptors including E-cadherin, N–cadherin, P-cadherin,
VE-cadherin [1]. Classical cadherin molecules, especially E-
cadherin and N-cadherin are involved intimately in the
pathogenesis of various cancers such as breast cancer,
esophageal cancer, prostate cancer, gastric cancer etc. [2-5].
The loss of E-cadherin and the up-regulation of N-cadherin
influence the behaviors of many types of cancers which
process is also known as cadherin switch [6]. Considering
the important function of cadherin in cell-cell contacts,
they are usually postulated to play a vital role in cancer
metastasis.
Colorectal cancer is one of the most common cancer
types worldwide and its incidence increases with the
change of life style and dietary structure [7]. Colorectal
cancer has the propensity to colonize the liver and leads
to a poor prognosis in the patient. However, metastasis
is a complex process and has not been fully understood.
We hypothesized that the destruction of cadherin adhe-
sions acts as a promoter to facilitate the metastasis of
colorectal cancer. In this article, we identified CDH12 as
such an important molecule. CDH12 is also known as
brain cadherin, because it is first identified in the brain
and it can promote the differentiation of nervous system
in mammary animal. In addition, CDH12 is associated
with the pathogenesis of some neuropsychiatric disor-
ders [8,9]. The comprehensive influence of classical cad-
herins on cancer such as E-cadherin and N-cadherin has
been deeply clarified. However, the impact of CDH12 on
cancer didn’t attract more attention until recent years.
Gemma Armengol et al. verified that CDH12 plays a sig-
nificant role in the progression of non-small-cell lung
cancer, and patients without CDH12 mutations have a
longer survival than those with CDH12 mutation. This
indicates that CDH12 acts as a tumor suppressor gene
in the non-small-cell lung cancer [10]. In addition, CDH12
is able to promote the migration and invasion ability of sal-
ivary adenoid cystic carcinoma [11]. However, the function
of CDH12 in colorectal cancer is unclear. In our research,
we demonstrated the down-regulation of proliferation, in-
vasion and migration ability in colorectal cancer cell lines
by silencing CDH12 expression. Furthermore, we showed
down-regulation of CDH12 can obviously inhibit the
process of angiogenesis, implying that CDH12 may play an
important role in tumor metastasis.
Methods
Cell culture
Seven human CRC cell lines were purchased from
American Type Culture Collection (Manassas, VA,United States). All the cell lines are preserved by
Shanghai Digestive Surgery Institute. SW1116, SW480
and SW620 are cultured in Leibovitz’s L-15 medium
supplemented with 10% fetal calf serum, and 2 mM
L -glutamine. HCT116, HT29, Caco2, LoVo and NCM460
were maintained in RPMI-1640 medium with the same
components. CRC cell lines were cultured in 37°C, 5% CO2
incubator. Total RNA and protein were extracted after
being incubated to 70-80% confluence.
Tissue microarray and immunohistological analysis
Tumor tissue and adjacent normal tissue of 56 patients
with specific diagnosis of CRC and laparoscopic surgery
in Minimally Invasive Surgery Centre, Ruijin Hospital,
Shanghai Jiaotong University were collected from 2009
to 2011. The collection of specimens was authorized by
Ethics Committee of Ruijin Hospital. None of the pa-
tients received preoperative treatment such as radiation
or chemotherapy. The patients include 33 males, 23 fe-
males and the median age is 65.Staging of CRC tumor
tissue was performed in accordance with the TNM clas-
sification provided by World Health Organization [12].
All the specimens fixed by 10% formaldehyde and
embedded with paraffin were made into microarray. The
staining of tissue microarray was conducted according
to the manufacturer’s protocol. After being dewaxed
and hydrated, the microarray was antigen-retrieved by
microwaving in citrate buffer (10 mM citric acid, pH
6.0), blocked in 5% animal serum, and stained for 2 h at
37°C by using primary antibody. Next ,the microarray
was stained for 10 min at 37°C by using secondary
biotinylated anti-rabbit antibodies at a 1:100 dilution
followed by streptavidin-HRP. Specimens were devel-
oped by DAB and the nucleus was counterstained by
Hematoxylin. The sections were photographed under a
microscope and analyzed by two pathologists without
knowing the pathological materials. Staining results were
evaluated following the standard provided by Shimazui
T et al. [13,14]. When the CDH12 were uniformly
expressed, heterogeneously expressed or none-expressed
in the tissue, the sections were evaluated as uniformly
CDH12 positive (+), heterogeneous (+/−), or uniformly
negative (−), respectively.
Quantitative reverse transcription polymerase
chain reaction
Total RNA was extracted with TRIzol (Invitrogen,
Carlsbad, CA, United States) and the concentration was
measured by spectrophotometer. Reverse transcription
was performed to synthesize cDNA using reverse tran-
scription kit(Invitrogen, CA, United States). The reaction
was performed in an Applied Biosystems 7500 System with
the mixture of cDNA, primers and Power SYBR Green
PCR Master Mix (2×, Applied Biosystems, Warrington,
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GGTGGGGAGGAAGATA-3′, antisense primer: 5′-CAT-
ATGTGGCCAGTGAATCG-3′. To quantify the expression
level of CDH12, we use GAPDH as a control. GAPDH
PCR sense primer: 5′-CCACGGAGCCGAAAACTAAAG-
3, antisense primer: 5′-GTAGCCCAGGATGCCCTTGA-3′.Western blot analysis
Protein lysates were prepared from collected cells with
RIPA and the supernatant was collected after being
reacted for 30 min on the ice, centrifuged for 15 min at
13000 rpm. BCA (bicinchonininc acid) was used to de-
termine protein concentration. An equal amount of pro-
tein (50 μg) from each condition was subjected to 12.5%
SDS-PAGE. Western blotting was carried out using the
primary antibodies: rabbit polyclonal anti-CDH12 anti-
body (Abcam), 1:100; mouse polyclonal anti–GAPDH
antibody,1:5000 for overnight at 4°C, followed by incuba-
tion with fluorescence-labeled secondary antibody for 2
h at room temperature. LI-COR Odyssey Infrared fluor-
escence scanner was used to capture the images.RNAi
3×105 cells were seeded into six-well plate each cham-
ber. Until 70% confluence, GFP-labeled shRNA targeting
CDH12 was transfected into cells mediated by Lipofecta-
mineTM 2000 according to the instruction. Cell sections
transfected with GFP-labeled shRNA targeting nonho-
mologous gene to CDH12 and LipofectamineTM 2000
only were performed as control. After 12 hours transfec-
tion, cells were observed under fluorescence microscope.Figure 1 Immunohistochemical results of CDH12 expression in surgic
patients with colon cancer. A-C: Uniformly negative (−), heterogeneous (
(200×); D-F: Uniformly negative (−), heterogeneous (+/−), and uniformly poShRNA oligonucleotides screen
The following shRNA oligonucleotides were used to inter-
fere CDH-12 expression and the most effective oligo-
nucleotide was screened with determining the mRNA














Cells were seeded in 96-well plate and cultured in 37°C,
5% CO2 incubator. Three groups (shCDH12 group,
shNC group and Mock group) were designed with 6
copies each group. The viability of cells was determined
at 0 h, 24 h, 48 h, 72 h, 96 h and 120 h. At the test point,
10 μL CCK-8 was added into each well and the plate
was incubated at 37°C for 2 h followed OD detection
using spectrophotometer.
Cell invasion and migration assay
Transwell chamber was used (8 mm, 24-well format;
Corning, Lowell, MA, USA) to perform cell invasion andal specimens of tumor tissues or adjacent normal tissue from
+/−), and uniformly positive (+) staining in adjacent normal mucosa
sitive (+) staining in CRC tumor tissues (200×).
Table 1 The expression of CDH12 in tumor tissues and
adjacent normal tissues
Classification n CDH12(−) CDH12(+/−) CDH12(+) P value
Tumor tissue 56 5 41 <0.001
Normal tissue 56 23 24 9
Table 2 Relationship between CDH12 expression level
and clinicopathologic variables in 56 CRC patients
Classification CDH-12(−) CDH-12(+/−) CDH-12(+) P value
Gender
Male 3 7 23 0.725
Female 2 3 18
Age (year)
≤65 2 4 19 0.915
>65 3 6 22
Tumor location
right hemicolon 0 1 11 0.283
left hemicolon 1 1 1
sigmoid colon 2 4 8
rectum 2 4 21
Tumor size (cm)
≤4×3 3 7 23 0.725
>4×3 2 3 18
TNM stage
invasion depth
T1 2 0 1 0.024
T2 1 1 4
T3 2 8 34
T4 0 1 2
lymph node
N0 1 5 18 0.237
N1 4 2 16
N2 0 3 7
organ metastasis
M0 4 10 38 0.365
M1 1 0 3
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L-15 serum-free medium containing 3×105 cells was
added into the upper chamber and 600 μL Leibovitz’s L-
15 with 10% serum was added into the lower chamber.
The chamber was cultured in 37°C, 5% CO2 condition
for 24 h. In invasion assay, the insert membranes were
coated with diluted Matrigel (BD Biosciences) and per-
formed in the same way as migration assay. Finally, cells
on the top side of the inserts were removed with cotton
swab. Chambers were fixed with methanol and Cells
under the inserts were stained with 1% crystal violet
for 30 min before rinsing with phosphate buffered
saline (PBS) for 20 min. The results are shown as
means ± sd. Each experiment was done in triplicate.
The wound healing assays was performed as previously
described [15,16].
Flow cytometric cycle analysis
CRC cells were collected after 24 h, 48 h respectively
and rinsed by PBS for twice. Collected cells were fixed
in 75% iced ethanol for detection. Fixed cells was recol-
lected by washing in PBS for twice, centrifuging at 1800
rpm for 5 min. RNAase (3 μL) and Propidium iodide
(PI, 50 μL) were added into each tube, incubated for 30
min at 37°C in the darkness. The Cell cycle analysis was
performed using BD FACS Vantage System (Becton,
Dickinson and Company, Franklin Lakes, NJ, United
States) according to the manufacturer’s protocol.
Cell aggregation assay
Cells were harvested with trypsin/EDTA and resupended
at 1.5×105 cells per ml in RPMI-1640 medium with FBS.
20 μL drops containing 5000 cells per drop were
pipetted onto the inner surface of the lid of petri plate.
The lid were then reversed and placed on the petri plate
with the drop hanging on the lid so that the cells failed
to adhere to the petri plate. 4 ml of PBS was placed in
the petri plate to eliminate evaporation within the
hanging drops and the results were observed under
microscope.
Cell adhesion assay
Human umbilical vein endothelial cells (HUVEC) were
plated into 24-well plate and incubated at 37°C, 5% CO2
for 24 h to form monolayer. Tumor cells after being
managed respectively were collected with trypsin/EDTAand resuspended by RPMI-1640 medium. 700 μL medium
containing 20,000 cells were subsequently added into each
well and incubated in the incubator for 6 h. Subsequently,
medium in each well was abandoned and the wells were
washed by PBS for three times. Results were observed
under fluorescence microscope and five random views were
chosen to quantify.Endothelial tube formation assay
Each well of prechilled 96-well plates was coated with a
thin layer of the Matrigel (50 μL/well) which was incu-
bated to polymerize at 37°C for 1 h. Human umbilical
vein endothelial cells (HUVEC) were resuspended in the
supernants collected from shRNA group, control groups.
Add 300 μL of the supernants to each well containing
4×104 HUVEC cells and incubated at 37°C, 5% CO2 for
Figure 2 Expression of CDH12 in CRC cell lines and the interfering effect of shRNA. A: CDH12 expression in CRC cell lines detected by
western blot; B: Relative average grey level of western blot bands; C: Interfering effects of shCDH12 in SW1116 were detected using western blot;
D: mRNA expression levels of CHD12 in SW1116 cell lines transfected with shRNAs (*P<0.05).
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formation ability by counting the tubular number, the
tubular length and tubular intersecting nods in using Image
Pro Plus software (Media Cybernetics Inc., Bethesda, MD,
USA) according to Mirshahi’s method [17]. Each experi-
ment was performed at least three times.Statistical analysis
All the data were analyzed by SAS 8.0 statistical soft-
ware. The difference of CDH12 expression between
tumor tissue and adjacent normal tissue was examined
by Cochran- Maantel-Terpstra test. Chi-square test and
Fisher exact probability method was used to analyze
the relationship between CDH12 expression level and
clinical features. Survival probabilities were calcu-
lated using Kaplan–Meier method, differences be-
tween two groups were determined using the log-rank
test. Multiple comparisons were performed by one-wayTable 3 The absorbance in the proliferation assay
Group 24 h 48 h 72 h 96 h 120 h
shCDH12 0.28±0.038 0.49±0.060 0.62±0.078 1.08±0.245 2.68±0.531
shNC 0.33±0.023 0.62±0.108 1.06±0.121 3.02±0.168 3.82±0.125
Mock 0.38±0.105 0.63±0.095 1.36±0.131 3.23±0.125 3.92±0.043analysis of variance. P<0.05 was considered statistically
significant.Results
The expression levels of CDH12 in CRC patients are
significantly correlated with invasion depth.
Immunohistochemistry tissue microarray staining was
performed to detect the expression of CDH12 in the
CRC tissue, and the representative results were shown in
Figure 1. 41 cases out of the 56 tumor samples exhibited
a substantial increase in overall CDH12 expression, 10
cases expressed heterogeneously and 5 cases expressed
uniformly negative. Obvious difference between tumor
tissues and adjacent normal tissues was verified by stat-
istical analysis, the positive rate is significantly higher in
the tumor tissues compared to the adjacent normal
tissues (Table 1). The expression level of CDH12 is sig-
nificantly correlated with invasion depth (P=0.024).
However, there are no significant relationships between
the CDH12 expression and other clinicopathologic fea-
tures such as gender, age, tumor size, or lymph node
metastasis (P>0.05) (Table 2). In addition, to further
elucidate the clinico-pathologic significance of CDH12
overexpression in CRC with prognosis, we correlate
CDH12 expression in CRC tissues with the survival time
44 out of 50 patients that were successfully followed up.
Figure 3 Effect of CDH12 on cell proliferation and cell cycle in CRC cell lines. A. Cell numbers at 0, 24, 48, 72,96 and 120 h was measured
by CCK-8 assays. B: Proportion of cells in various phases of the cell cycle. The results are means of three independent experiments ± S.D (*:P<0.05). C:
Representative histograms depicting cell cycle profiles of cells transiently transfected with shCDH12 or controls.
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rate of the CDH12 positive patients group was signifi-
cantly lower than the CDH12 negative patients group
(P<0.05, Additional file 1: Figure S1).
Expression of CDH12 in CRC cell lines and the interfering
effect of shRNA
Western blot was used to detect the CDH12 expression
in CRC cell lines, including the non-cancer cell line
NCM460. CDH12 was expressed in all these cell lines,
and especially high in SW1116 and SW620, but low in
HT29 and HCT116 (Figure 2B&C, Additional file 2:
Figure S2B&C). In order to explore the functions of
CDH12 in CRC cell lines, we chose the CHD12 high-
expression cell lines SW1116 and SW620. The three
shRNAs targeting CDH12 or a scramble control shRNA
was transfected into SW1116 or SW620 and the expres-
sions of CDH12 were detected (Additional file 2: Figure
S2A). The results showed that the expression of CDH12
was significantly decreased in shRNA-CDH12 transfection
cells compared with the control groups (Figure 2C, 2D).
Down-regulation of CDH12 can inhibit CRC cells
proliferation and block cell cycle progression
We next determined whether CDH12 could affect the cell
proliferation and cell cycle. The proliferation ability of
SW1116 was examined at six time points (0 h, 24 h, 48 h,
72 h, 96 h and 120 h) after being transfected with shRNAs.
The results was shown as means ± SD (Table 3) and theproliferation curves (Figure 3A). Cell proliferation ability in
shCDH12 group was decreased significantly compared with
the control groups (P<0.01). Consistently, ectopic expres-
sion of CDH12 in HT29 and HCT116 promotes the prolif-
eration of the CRC cells (Additional file 3: Figure S3A&D,
P<0.01).
To further detect the influence of CDH12 on cell cycle,
we performed flow cytometric cell cycle analysis to examine
which phase of cell cycle was influenced by CDH12 in
SW1116. Flow cytometric analysis demonstrated that
proportions of cells in shCDH12 group at S phase is more
than that in shNC group and Mock group (*P<0.05,
Figure 3B&C). These data indicated that down-regulation
of CDH12 could obviously block cells in S phase.
Down-regulation of CDH12 inhibits wound healing ability,
migration and invasion of CRC cells
Wound healing assay was used to examine migration
ability of SW1116 and SW620. Cells was plated in 12-
well plate after being transfected and scratched by 20 μL
sterile pipet tips. Results were showed in Figure 4A&C.
Three lines were drawn in each group and relative
length were calculated which is showed in Figure 4B&D.
After 48 h incubation, the distance of the scratch woud
in shCDH12 group is significantly larger compared with
control groups. (The woud diatance: shCDH12 group:
1.07±0.11, shNC group: 0.17±0.06, Mock group: 0.20±0.17),
The similar results were observed in theSW620 cell line
(shCDH12 group: 1.08±0.05, shNC group: 0.18±0.06, Mock
Figure 4 Wound healing assay. A: Representative photographs of scratch wounds in SW1116 (100×), B: Relative distances of cell wounds in
shCDH12, shNC and Mock group (*:P<0.05), C: Representative photographs of scratch wounds in SW620 (100×); B: Relative distances of cell
wounds in shCDH12, shNC and Mock group (**:P<0.01).
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CDH12 in HT29 and HCT116 promotes wound healing
ability of CRC cells. (HT29, CDH12 group: 0.18±0.05, Vec-
tor group: 0.99±0.13; HCT116, CDH12 group: 0.20±0.06,
Vector group: 0.83±0.07,) (Additional file 3: Figure S3 B&C
and E&F).
To further detect the influence of CDH12 on migra-
tion and invasion, we performed transwell migration
and invasion assay. In transwell migration assay, the
number of cells migrating through the chamber in
shCDH12 was 85±18.42 which was lower than in shNC
group (115.6±11.26) and mock group (141±15.17).
The same result was also observed in the invasion
assay: shCDH12 group: 37.80±11.28, shNC group:
78.40±13.05, Mock group: 93.60±8.91 (Figure 5A-D,
*P<0.05). Similarly, the results are implemented in
SW620 cell lines. (Migration assay: shCDH12 group:
78.4±10.38, shNC group: 120±8.7, Mock group: 135±9.8.
sh; Invasion assay: shCDH12 group: 33±10.07, sh-NC
group: 55.8±9.52, Mock group: 60.8±10.87). (**P<0.05,
Figure 5E-H). Consistently, ectopic expression of CDH12
in HT29 and HCT116 promotes the migration and inva-
sion of CRC cells (Additional file 4: Figure S4, *P<0.05,
**P<0.01).CDH12 can promote cell-cell junction formation
As a member of the cadherin family, CDH12 is likely to
influence the cell-cell junction. We firstly performed the
cell aggregation assay to examine the role of CDH12 in
cell-cell junction. The results demonstrated that sup-
pression of CDH12 can inhibit the formation of cell col-
ony because the cells in CDH12 knock-down groups
distribute more dispersedly compared with control
groups (Figure 6A). We performed adhesion assay sub-
sequently to examine the adhesion ability of SW1116 to
endothelial cells after CDH12 being decreased. After be-
ing washed with PBS, the number of SW1116 cells ad-
hered to the HUVEC monolayer in the shCDH12 group
was less than the shNC group (Figure 6B, 6C).These
suggest that CDH12 is an essential adhesion molecule
not only to tumor cells junctions but also to the adhe-
sion between tumor cells and endothelial cells.
CDH12 can promote endothelial tube formation
Human umbilical vein endothelial cells (HUVECs)
(4×104cells/well) were suspended in supernatants col-
lected from shCDH12 group, shNC group and Mock
group. After being incubated for 24 h, tubular numbers
of each group were assessed under microscope. The
Figure 5 Transwell cell migration and invasion assay. A: Representative photographs of migratory SW1116 cells on the membranes. B: Cell
numbers were counted at random five views, the average number of migratory cells were shown as histogram. (*:P<0.05). C: Representative
photographs of invasive SW1116 cells on the membranes. D: Cell numbers were counted at random five views, the average number of invasive
cells were shown as histogram. (*:P<0.05), E: Representative photographs of migratory SW620 cells on the membranes. F:Cell numbers were
counted at random five views, the average number of migratory cells were shown as histogram. (**:P<0.01). G: Representative photographs of
invasive SW620 cells on the membranes. H: Cell numbers were counted at random five views, the average number of invasive cells were shown
as histogram. (**:P<0.01).
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inhibiting effect on endothelial tube formation compared
with shNC group and Mock group whatever in tubular
number and tubular intersecting nods (Figure 7).Discussion
CDH12 protein belongs to type II transmembrane pro-
tein containing 794 amino acids with a molecule weight
of 88kDa and functions in the Ca2+-dependent cell-cell
Figure 6 Cell aggregation assay and cell adhesion assay. A:The formation of cell colony was obviously inhibited in shCDH12 group
compared with control groups. B: Cell numbers adhered to HUVEC monolayer in shCDH12 group is less than negative control group after PBS
elution which demonstrated the function of CDH12 in tumor cell and endothelial cell junction. As the transfectant (shRNA and scrambled shRNA)
is marked with GFP, so the cells adhered to the monolayer was showed as green dots. C: The numbers of the cells were counted in five random
views and the statistical result is presented as histogram (*P<0.05).
Zhao et al. Journal of Translational Medicine 2013, 11:288 Page 9 of 11
http://www.translational-medicine.com/content/11/1/288junction. CDH12 can promote the migration and inva-
sion ability of salivary adenoid cystic carcinoma [11]. Ac-
cording to our findings, CDH12 may be an oncogene
and promote the malignant progression of CRC cells.
Our findings showed that CDH12 expression is sub-
stantially upregulated in CRC tissues compared to adja-
cent normal tissue according to the histochemistry
microarray analysis, indicating that CDH12 may also
contribute to tumorigenicity in CRC. In addition, the ex-
pression of CDH12 is significantly associated with inva-
sion depth. These data suggests that CDH12 may be
associated with CRC invasion and metastasis. We se-
lected the CDH12 high-expression cell lines SW1116
and SW620, and successfully inhibited CDH12 expres-
sion in them by shRNA. After CDH12 abrogation, themigration and invasion ability of SW1116 or SW620 was
severely impaired.
These results verified the important role of CDH12 in
CRC cells migration and invasion behavior and which
may be explained that CDH12 is related to several intra-
cellular metastasis-associated signal molecules that can
promote tumor cell migration. This is consistent with
the report that CDH12 is able to promote the migration
and invasion ability of salivary adenoid cystic carcinoma
[11].
We also performed cell aggregation assay and adhe-
sion assay to further determine the importance of
CDH12 in intercellular junction. Cell aggregation assay
showed that the absence of CDH12 leads cells to distrib-
ute more dispersedly compared with control groups.
Figure 7 Endothelial tube formation assay. Effect of suppressing CDH12 expression on tubular formation in vitro. The supernatants from cells
with or without CDH12 suppression were collected which was used to suspend HUVEC. After 24 h co-cultivation, tubular formation was evalu-
ated. A: Poorly formed tubular structure was observed in shRNA group, compared with negative control group and mock group. B: The chart
represent the counting of tubules numbers (**P<0.001); C: The intersecting nods (**P<0.001), The data represent the mean±SD of three
independent experiments.
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tumor cell metastasis which manifests with repression of
cell adhesion molecules. This process may be also
known as epithelial-mesenchymal transition (EMT) [18].
Reduced intracellular adhesion may allow tumor cells to
disseminate and spread throughout the extracellular
matrix. Generally, tumor cells gaining the ability to leave
the site and metastasize are accompanied with “cadherin
switching” [6]. CDH12 may also promote tumor metas-
tasis through this switching mechanism. Simultaneously,
adhesion assay that cells numbers attached to the
HUVEC monolayer in shCDH12 group were less than
the control group, revealed the importance of CDH12 in
the adhesion of tumor cells to endothelial cell. In the
process of tumor metastasis, the arrest of circulating
tumor cells to luminal walls of distant organ microvas-
culature is an essential part of this process [19]. Collect-
ively, the result demonstrates that CDH12 may promote
tumor cells to attach to the vascular enthelial cells dur-
ing tumor metastasis.
Tumors require supplements of nutrients and oxygen
and evacuation of metabolic wastes and carbon dioxide
as normal tissues. The tumor-associated neovasculature,
generated by the process of angiogenesis, not only
supplies abundant nutrients for tumor cell but also pro-
vides conveniences for tumor cell dissemination [20].
Our results showed that down-regulation of CDH12 on
SW1116 or SW620 cells effectively inhibited the forma-
tion of vessel. The numbers of tube, tubular length andtubular intersecting nods in shRNA group is less than
the control. This suggests that CDH12 can promote the
process of angiogenesis. Considering the importance of
angiogenesis in tumor metastasis and the contribution
of CDH12 in tumor cell migration, invasion and cell
cycle, CDH12 maybe a potential target to supervise
tumor cell malignant metastasis.
Conclusion
Our results showed that CDH12 promotes proliferation,
migration, invasion, adhesion and angiogenesis, suggesting
that CDH12 may be an oncogene in colorectal cancer.
CDH12 is expected to become a new diagnostic and prog-
nostic marker and a novel target of the treatment of colo-
rectal cancer. More efforts should be put to clarify the
signal pathways underlying these biological phenomenon.
Additional files
Additional file 1: Figure S1. Kaplan-Meier survival analysis of CDH12
expression in 50 CRC patients. The Kaplan-Meier survival analysis showed
the survival rate of the CDH12 positive patients group was significantly
lower than in the CDH12 negative patients group.
Additional file 2: Figure S2. Expression of CDH12 in CRC cell lines and
the result of shRNAs sequence screening. A: The Interfering effects of
three shRNAs targeting CDH12 in SW1116 and SW620, B: CDH12
expression in CRC cell lines detected by western blot; C: Relative average
grey level of western blot bands.
Additional file 3: Figure S3. Effect of enforcing CDH12 on cell
proliferation and wound healing in CRC cell lines. A: Growth curves of
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http://www.translational-medicine.com/content/11/1/288HT29 cell lines were measured by CCK-8 assays. B: Representative photo-
graphs of scratch wounds in HT29 (100×), C: Relative distances of cell
wounds in CHD12 ectopic expression group and control group (*P<0.05,
**P<0.01), D: Growth curves of HT29 cell lines were measured by CCK-8
assays. E: Representative photographs of scratch wounds in HCT116
(100×); F: Relative distances of cell CHD12 ectopic expression group and
control group (*P<0.05, **P<0.01).
Additional file 4: Figure S4. Ectopic expression of CDH12 promotes
migration and invasion of CRC cells. A: Representative photographs of
migratory or invasive HT29 cells on the membrane. B: Average number of
migratory or invasive HT29 cells (*P<0.05). C: Representative photographs
of migratory or invasive HCT116 cells on the membrane. D: Average
number of migratory or invasive HCT116 cells (*P<0.05). The data
represent the mean ± s.d. of three independent experiments.
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